Capricor Therapeutics’ General Counsel Karen Krasney dumped 24K shares worth $732K just before a stock dip—though she exercised options first, the move signals caution. The biotech, up 200% last year but down 30% this year, still burns cash but has runway to 2027. The real focus? The looming FDA decision on their Duchenne muscular dystrophy treatment Deramiocel, with a decision expected August 22. Analysts are bullish—if approved, it could ignite the stock after this pullback. This insider sale? Just one data point in a high-stakes bet on science and regulatory wins.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
